Increased arterial diameters in the posterior cerebral circulation in men with fabry disease

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Üçeyler, Nurcan ^a   Homola, György A ^a   González, Hans Guerrero ^a   Kramer, Daniela ^a   Wanner, Christoph ^a   Weidemann, Frank ^a   Solymosi, László ^a   Sommer, Claudia ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ANTERIOR CEREBRAL ARTERY; ARTERY DIAMETER; ARTICLE; BASILAR ARTERY; BRAIN BLOOD FLOW; BRAIN ISCHEMIA; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME REPLACEMENT; FABRY DISEASE; FEMALE; HUMAN; KIDNEY DYSFUNCTION; MAGNETIC RESONANCE ANGIOGRAPHY; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTERIOR CEREBRAL ARTERY; RETROSPECTIVE STUDY; TRANSIENT ISCHEMIC ATTACK; WHITE MATTER LESION;

CEREBRUM; FABRY DISEASE; FEMALE; GERMANY; HUMANS; KIDNEY; MAGNETIC RESONANCE IMAGING; MALE; POSTERIOR CEREBRAL ARTERY; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC;

EID: 84900341800     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0087054     Document Type: Article

References (36)

1. Schiffmann R (2009) Fabry disease. Pharmacol Ther 122: 65-77.
2. Barbey F, Brakch N, Linhart A, Rosenblatt-Velin N, Jeanrenaud X, et al. (2006) Cardiac and vascular hypertrophy in Fabry disease: evidence for a new mechanism independent of blood pressure and glycosphingolipid deposition. Arterioscler Thromb Vasc Biol 26: 839-844. (Pubitemid 43732160)
3. Desnick RJ, Brady R, Barranger J, Collins AJ, Germain DP, et al. (2003) Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 138: 338-346. (Pubitemid 36205932)
4. Feldt-Rasmussen U (2011) Fabry disease and early stroke. Stroke Res Treat 2011: 615218.
5. Fellgiebel A, Müller MJ, Mazanek M, Baron K, Beck M, et al. (2005) White matter lesion severity in male and female patients with Fabry disease. Neurology 65: 600-602. (Pubitemid 41170723)
6. Moore DF, Altarescu G, Barker WC, Patronas NJ, Herscovitch P, et al. (2003) White matter lesions in Fabry disease occur in 'prior' selectively hypometabolic and hyperperfused brain regions. Brain Res Bull 62: 231-240. (Pubitemid 38091711)
7. Sims K, Politei J, Banikazemi M, Lee P (2009) Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry. Stroke 40: 788-794.
8. Rolfs A, Fazekas F, Grittner U, Dichgans M, Martus P, et al. (2013) Acute cerebrovascular disease in the young: the Stroke in Young Fabry Patients study. Stroke 44: 340-349.
9. Hilz MJ, Kolodny EH, Brys M, Stemper B, Haendl T, et al. (2004) Reduced cerebral blood flow velocity and impaired cerebral autoregulation in patients with Fabry disease. J Neurol 251: 564-570. (Pubitemid 38680299)
10. Moore DF, Altarescu G, Ling GS, Jeffries N, Frei KP, et al. (2002) Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement. Stroke 33: 525-531. (Pubitemid 34123400)
11. Üçeyler N, He L, Kahn AK, Breunig F, Mullges W, et al. (2012) Cerebral blood flow in patients with Fabry disease as measured by Doppler sonography is not different from that in healthy individuals and is unaffected by treatment. J Ultrasound Med 31: 463-468.
12. Fellgiebel A, Keller I, Marin D, Muller MJ, Schermuly I, et al. (2009) Diagnostic utility of different MRI and MR angiography measures in Fabry disease. Neurology 72: 63-68.
13. Fellgiebel A, Keller I, Martus P, Ropele S, Yakushev I, et al. (2011) Basilar artery diameter is a potential screening tool for Fabry disease in young stroke patients. Cerebrovasc Dis 31: 294-299.
14. Üçeyler N, He L, Schönfeld D, Kahn AK, Reiners K, et al. (2011) Small fibers in Fabry disease: baseline and follow-up data under enzyme replacement therapy. J Peripher Nerv Syst 16: 304-314.
15. Schiffmann R, Warnock DG, Banikazemi M, Bultas J, Linthorst GE, et al. (2009) Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant 24: 2102-2111.
16. Tahir H, Jackson LL, Warnock DG (2007) Antiproteinuric Therapy and Fabry Nephropathy: Sustained Reduction of Proteinuria in Patients Receiving Enzyme Replacement Therapy with Agalsidase-beta. J Am Soc Nephrol 18: 2609-2617. (Pubitemid 47378878)
17. Vedder AC, Linthorst GE, Houge G, Groener JE, Ormel EE, et al. (2007) Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg. PLoS ONE 2: e598.
18. Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA (1987) MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJR Am J Roentgenol 149: 351-356. (Pubitemid 17104996)
19. Garzuly F, Marodi L, Erdos M, Grubits J, Varga Z, et al. (2005) Megadolichobasilar anomaly with thrombosis in a family with Fabry's disease and a novel mutation in the alpha-galactosidase A gene. Brain 128: 2078-2083. (Pubitemid 41253275)
20. Mitsias P, Levine SR (1996) Cerebrovascular complications of Fabry's disease. Ann Neurol 40: 8-17. (Pubitemid 26250137)
21. Moore DF, Scott LT, Gladwin MT, Altarescu G, Kaneski C, et al. (2001) Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy. Circulation 104: 1506-1512. (Pubitemid 32917343)
22. Moore DF, Ye F, Brennan ML, Gupta S, Barshop BA, et al. (2004) Ascorbate decreases Fabry cerebral hyperperfusion suggesting a reactive oxygen species abnormality: an arterial spin tagging study. J Magn Reson Imaging 20: 674-683. (Pubitemid 39313744)
23. Moore DF, Herscovitch P, Schiffmann R (2001) Selective arterial distribution of cerebral hyperperfusion in Fabry disease. J Neuroimaging 11: 303-307. (Pubitemid 32625278)
24. Kahn P (1973) Anderson-Fabry disease: a histopathological study of three cases with observations on the mechanism of production of pain. J Neurol Neurosurg Psychiatry 36: 1053-1062.
25. Kaye EM, Kolodny EH, Logigian EL, Ullman MD (1988) Nervous system involvement in Fabry's disease: clinicopathological and biochemical correlation. Ann Neurol 23: 505-509.
26. Laforet P, Petiot P, Nicolino M, Orlikowski D, Caillaud C, et al. (2008) Dilative arteriopathy and basilar artery dolichoectasia complicating late-onset Pompe disease. Neurology 70: 2063-2066.
27. Franzen D, Krayenbuehl PA, Lidove O, Aubert JD, Barbey F (2013) Pulmonary involvement in Fabry disease: Overview and perspectives. Eur J Intern Med.
28. Crutchfield KE, Patronas NJ, Dambrosia JM, Frei KP, Banerjee TK, et al. (1998) Quantitative analysis of cerebral vasculopathy in patients with Fabry disease. Neurology 50: 1746-1749. (Pubitemid 28283245)
29. Ginsberg L (2006) Nervous system manifestations of Fabry disease: data from FOS - the Fabry Outcome Survey. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry Disease: Perspectives from 5 Years of FOS. Oxford.
30. Acharya D, Robertson P, Kay GN, Jackson L, Warnock DG, et al. (2012) Arrhythmias in Fabry cardiomyopathy. Clin Cardiol 35: 738-740.
31. Okeda R, Nisihara M (2008) An autopsy case of Fabry disease with neuropathological investigation of the pathogenesis of associated dementia. Neuropathology 28: 532-540.
32. Duning T, Deppe M, Brand E, Stypmann J, Becht C, et al. (2013) Brainstem involvement as a cause of central sleep apnea: pattern of microstructural cerebral damage in patients with cerebral microangiopathy. PLoS ONE 8: e60304.
33. Jardim L, Vedolin L, Schwartz IV, Burin MG, Cecchin C, et al. (2004) CNS involvement in Fabry disease: clinical and imaging studies before and after 12 months of enzyme replacement therapy. J Inherit Metab Dis 27: 229-240. (Pubitemid 38756339)
34. Albrecht J, Dellani PR, Muller MJ, Schermuly I, Beck M, et al. (2007) Voxel based analyses of diffusion tensor imaging in Fabry disease. J Neurol Neurosurg Psychiatry 78: 964-969. (Pubitemid 47310833)
35. Gavazzi C, Borsini W, Guerrini L, Della Nave R, Rocca MA, et al. (2006) Subcortical damage and cortical functional changes in men and women with Fabry disease: a multifaceted MR study. Radiology 241: 492-500. (Pubitemid 44632896)
36. Azevedo E, Mendes A, Seixas D, Santos R, Castro P, et al. (2012) Functional transcranial Doppler: presymptomatic changes in Fabry disease. Eur Neurol 67: 331-337.